Publicaciones Similares
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Consequences of the IRA for the pharma sector
Navigating Pharma’s Evolution: Dive into the consequences of the Inflation Reduction Act 2022. From drug refunds to taxes, Medicare changes, and R&D impacts, the industry is transforming. Stay competitive with our tailored resource solutions. Contact us to thrive amidst evolving pharmaceutical dynamics.
Biosimilars in Brazil
Brazil has designed a set of measures to increase investment in biopharmaceutical research and is promoting the production of national biological drugs.
Health System in Peru
The main challenge facing this system is to expand health care for the population that still does not receive basic services.
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.
Why are prices so high in the US?
An In-depth Analysis of High Prices in the U.S. Delve into the statistics, root causes, and strategic interventions shaping the economic landscape in our comprehensive infographic. Uncover the complexities, explore solutions.